Bryan R. Schumaker
Thank you, Jeff, and good afternoon, everyone. Please turn to Slide 6. Revenue in the quarter of $642 million was up 2% sequentially, in line with our prior guidance. Our non-GAAP EPS was $0.55, also at the midpoint of our prior guidance of $0.52 to $0.58. As a reminder, our non-GAAP results excluded stock-based compensation, amortization of intangible assets, restructuring and other expenses. For Q2, our non-GAAP gross margin was 10.2%, up 10 basis points sequentially and flat year-over-year. Non-GAAP operating margin was 4.7%, up 10 basis points sequentially, driven by our improvement in gross margin. Our second quarter non- GAAP effective tax rate was 24%, driven by geographic mix. Please turn to Slide 7 for our second quarter 2025 revenue performance by sector. Semi-cap revenue decreased 2% quarter-over- quarter but grew 11% year-over-year. Industrial revenue was up 4% quarter-over-quarter and flat year-over-year. In A&D, revenue was up 4% quarter-over-quarter and 16% year-over-year. Within Medical, revenue was up 6% versus the prior quarter and down low- single-digits year-over-year. Finally, AC&C revenue was flat quarter-over-quarter, while still down considerably year-over-year. Please turn to Slide 8 for trended non-GAAP financials. As you see, despite our flattish revenue performance over the past year, we have consistently delivered non-GAAP gross margin of 10% or more, which we expect to continue. With our anticipated revenue growth in the back half of the year, we are forecasting non-GAAP operating margin to again exceed 5%. Please refer to Slides 9 and 10 for a discussion of our balance sheet, cash flow and working capital trends. Our cash balance on June 30 was $265 million, a decrease of $90 million from Q1, driven by the following factors. During our Q1 earnings call, we highlighted that our Q2 free cash flow would be impacted by a couple of onetime events related to customs and transition tax payments related to prior years. The net effect of which we would be temporary pause -- a net effect which would be a temporary pause in our free cash flow generation. These charges, combined with our other working capital items and capital expenditures resulted in a $15 million free cash outflow during the quarter. As a reminder, we generated over $80 million in free cash flow over the trailing 12 months ended June 2025. We expect to return to positive free cash flow through the remainder of the year. During Q2 2025, we repatriated $152 million of cash from China and Thailand, $95 million of which we used to further pay down our revolver. In connection with this repatriation, we paid foreign withholding taxes of $15 million, the majority of which we anticipate recovering in 2026. As Jeff mentioned, the company completed a debt refinancing in June, which extended the maturity of our term loan and revolver to June 2030. It also increased our term loan to $150 million from $121 million. All other terms were consistent with our prior debt agreements. As of June 30, we had $150 million outstanding on our term loan and $60 million outstanding against our revolver from which we had $486 million available to borrow. Our Q2 2025 liquidity ratio as calculated by our debt covenants was 0.3, down from 0.7 in the prior year period. We invested approximately $12 million in capital expenditures during the quarter, primarily to enhance capabilities and infrastructure at our Americas and Asia facilities, supporting long-term growth and operational efficiency. Demonstrating our ongoing commitment to return value to shareholders, we returned $6 million in cash dividends and repurchased $8 million in stock during the quarter. At the end of the quarter, we had approximately $134 million remaining in our existing share repurchase authorization. Our cash conversion cycle in the quarter was 85 days, improving 1 and 5 days sequentially and year-over-year, respectively. Inventory days were down 6 days sequentially as we continue to actively manage our inventory. Please advance to Slide 11. Let me now turn to our guidance for our third quarter of 2025. We expect revenue to be within a range of $635 million to $685 million, up low-single-digits sequentially. We continue to anticipate year-over-year growth of low- to mid-single digits in the second half. We expect non-GAAP gross margin to be between 10.2% and 10.4%. With those assumptions, we would expect non-GAAP operating margin to be between 5% and 5.2%. On a GAAP basis, we expect expenses to include approximately $5.3 million of stock-based compensation and $6.1 million to $6.3 million of nonoperating expenses, including amortization, restructuring and other charges. Our non-GAAP diluted earnings per share is expected to be in the range of $0.56 to $0.62. Interest and other expenses are expected to be approximately $5.5 million. We expect our Q3 effective tax rate will be between 23% and 25%. Our weighted average share count is expected to be approximately 36.3 million. With that, I would like to turn the call over to David to discuss market sector performance and outlook. David?